L-Carn

Levocarnitine, the active ingredient in L-Carn, is a carnitine presented as a intravenous solution for intravenous use. It treats primary and secondary carnitine deficiency and metabolic disorders requiring carnitine supplementation.

GNH USA supplies L-Carn as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

L-Carn is used to address disorders of carnitine metabolism and related energy‑production pathways.

Primary carnitine deficiency: restores intracellular carnitine stores and supports fatty‑acid oxidation. Secondary carnitine deficiency: compensates for acquired loss of carnitine and improves metabolic stability. Metabolic disorders requiring carnitine supplementation: enhances mitochondrial β‑oxidation and assists in energy generation.

Adverse reactions may occur with intravenous levocarnitine administration.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis following infusion. - Headache: transient cranial discomfort. - Mild hypotension: temporary drop in blood pressure. - Injection site pain: local discomfort at the infusion site. - Metallic taste: brief alteration in taste perception.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked blood pressure decline. - Arrhythmia: irregular heart rhythm. - Hepatic dysfunction: abnormal liver enzyme elevations. - Metabolic acidosis: significant acid‑base imbalance. - Seizures: rare neurologic events.

Safety considerations should be observed when using L-Carn. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic disease: use with caution; observe liver function tests. - Concomitant valproic acid: increased risk of hyperammonemia; monitor ammonia levels. - Pregnancy: safety not established; weigh potential benefits against risks. - Breastfeeding: unknown excretion in milk; consider alternatives. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions require attention.

Major Interactions (Avoid): - Valproic acid: may increase ammonia accumulation. - Warfarin: possible alteration of anticoagulant effect. - Phenobarbital: induces metabolism, reducing levocarnitine levels. - Cyclosporine: heightened nephrotoxicity risk. - High-dose insulin: may exacerbate hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: electrolyte shifts may affect carnitine balance. - Statins: combined muscle toxicity potential. - Antibiotics (e.g., carbapenems): may interfere with renal clearance. - Antiepileptics: monitor for additive CNS effects. - Hormonal contraceptives: observe for altered plasma concentrations.